J.P. Morgan's Global China Summit Day 1 highlights steady growth in China's healthcare CXO sector, with AI beginning to turn into incremental business opportunities

Overview

This report summarizes the management discussion highlights from the first day of J.P. Morgan's Global China Summit in the China healthcare sector. The core conclusion is that the CXO growth outlook remains solid, leading companies are maintaining or strengthening their 2026 revenue and margin expectations, and AI's impact on drug discovery, protein synthesis, enzyme discovery, and CRO business is becoming more visible. The report focuses on companies such as WuXi XDC, Asymchem, GenScript, and Hansoh Pharma, and uses capacity expansion, backlog, business-mix upgrade, and BD potential to assess industry opportunities.

Core views

First, WuXi XDC continues to show strong confidence in growth, with commercialization manufacturing ramp-up, 8 PPQ projects, and the potential first BLA commercial project improving visibility for future projects; management kept full-year sales and gross margin guidance unchanged, and the report authors believe there is room for upside surprise. Second, Asymchem is expanding from small molecules into higher-barrier novel-modality platforms, and the 2026 backlog of US$1.385bn supports its revenue growth guidance, while the high growth and better gross margin profile of peptides, oligonucleotides, conjugation payloads, and biologics should lift consolidated margins over the next 2 to 3 years. Third, GenScript is extending its life science business from services into high-margin, shelf-ready products, with TurboCHO kits and AI-driven Bestzyme enzyme discovery representing an upgrade in the business model. Fourth, Hansoh Pharma expects double-digit growth in 2026 revenue even without new BD transactions, and may continue to pursue outbound licensing through ADC, autoimmune, IgAN, and CNS assets.

Analysis framework

The report uses a conference-note style analytical framework, mainly based on management statements at the Global China Summit, and organizes views around 2026 guidance, order and project visibility, capacity expansion pace, business-mix changes, AI implementation, productization strategy, and BD pipeline potential. As this is not a single-company deep-dive report, the focus is not on valuation models or target prices, but on judging industry fundamentals, company growth drivers, and follow-up catalysts.

Methodology notes

• Conference notesManagement discussion takeaway summary

  Use guidance, orders, capacity, projects, and strategic changes disclosed by management to judge industry and company fundamental trends.

  The report mainly relies on the first-day summit discussions, extracting each company's comments on FY26E growth, capacity expansion, AI adoption, productization, and BD opportunities to form a directional view of the industry.

• Industry analysisGrowth visibility and business-mix upgrade

  Assess future revenue and margin elasticity through backlog, commercial projects, readiness of capacity, and the share of high-margin businesses.

  WuXi XDC's PPQ and BLA projects, Asymchem's US$1.385bn backlog and higher share of novel-modality businesses, and GenScript's productization and AIDD demand are all used as evidence of improved growth visibility and earnings quality.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi XDC

  An ADC and XDC-related CXO company, and a key management discussion focus in the report.

  Strengths

  The 2026 growth path is clear, commercial manufacturing is ramping up rapidly, expansion at the Wuxi and Singapore sites is progressing as planned, and 8 PPQ projects plus the potential launch of the first BLA commercial project improve project visibility.

  Weaknesses

  Future growth still depends on commercial project conversion, capacity ramp-up, and customer project progress.

  Comparison

  Compared with CXO businesses centered on early-stage R&D services, WuXi XDC's commercial manufacturing and ADC-related capabilities provide stronger order and revenue visibility.

  Risks

  Delayed launch of the BLA commercial project, GMP readiness falling short of expectations, insufficient capacity utilization, or pricing/customer acceptance missing expectations.

• Asymchem

  A CDMO/CXO company benefiting from expansion from small molecules into higher-barrier novel-modality platforms such as peptides, oligonucleotides, conjugation payloads, and biologics.

  Strengths

  US$1.385bn in 2026 backlog supports the 19% to 22% revenue growth guidance; novel-modality businesses are growing 60% to 100%+ and have a better margin structure.

  Weaknesses

  The business transformation requires continued execution, and improvement in consolidated gross margin depends on the ramp-up of novel-modality businesses.

  Comparison

  Compared with a traditional small-molecule CDMO, Asymchem is securing higher growth and a better margin structure through higher-barrier novel-modality businesses.

  Risks

  Backlog conversion falling short, slower-than-expected ramp-up of novel-modality businesses, customer project cancellations or delays, or industry competition pressuring prices.

• GenScript

  A life science services and products company, with the report emphasizing its AIDD demand and productization strategy.

  Strengths

  Management estimates it captures about 50% of the incremental protein-synthesis demand from AIDD, and improves efficiency through high-margin, scalable products such as TurboCHO; the Bestzyme business is introducing AI to accelerate enzyme discovery and reduce costs.

  Weaknesses

  The strategic upgrade from services to product sales still needs market validation, and there is uncertainty around productized revenue scale and customer adoption speed.

  Comparison

  Compared with a pure service model, an off-the-shelf product model has greater scalability and gross-margin advantages.

  Risks

  Insufficient durability of AIDD demand, weaker-than-expected overseas TurboCHO sales, limited AI cost-reduction effect, and intensified competition with existing industry players.

• Hansoh Pharma

  A Chinese innovative drug company, with the report focusing on its 2026 growth guidance and potential BD transactions.

  Strengths

  The company expects double-digit growth in 2026 total revenue, product revenue, and BD-related revenue; pipeline assets such as Ameile indication expansion and the EGFR/c-MET bispecific combination regimen support medium- to long-term growth.

  Weaknesses

  No new BD transactions have closed yet, and part of the growth depends on indication approvals and pipeline progress.

  Comparison

  Compared with pharma companies that rely only on product sales, Hansoh Pharma has both product-revenue growth and outbound-licensing BD potential.

  Risks

  Failure to complete BD transactions, delays in approval or clinical progress for key drugs, competing drugs affecting sales, or Ameile growth falling below expectations.

Key data

• Asymchem 2026 backlogUS$1.385bnManagement said this backlog supports the full-year 2026 revenue growth guidance of 19% to 22%.
• Asymchem 2026 revenue growth guidance19%-22%Revenue visibility comes from backlog and business-mix upgrades.
• Asymchem novel-modality business revenue shareClose to 30%Peptides, oligonucleotides, conjugation payloads, and biologics together contributed close to 30% of 2025 revenue, and are growing at 60% to 100%+.
• Asymchem small-molecule gross margin baseline46%-47%Management said the steady-state gross margin for peptides and oligonucleotides is expected to exceed that of the small-molecule business.
• WuXi XDC PPQ projects8Management believes these process performance qualification projects provide visibility into future commercial projects.
• WuXi XDC XDP5 and XDP6 GMP readiness timing2027 to 2028Expansion at the Wuxi and Singapore bases continues, and readiness for advanced facilities to reach GMP status is proceeding as planned.
• GenScript AIDD incremental protein-synthesis demand shareAbout 50%Management estimates the life science business captures about 50% of the incremental protein-synthesis demand generated by AI for drug discovery.
• TurboCHO Protein Expression Kits launch timing2026-05GenScript said the product has been launched outside China and is an important part of its productization strategy.
• Hansoh Pharma 2026 revenue expectationDouble-digit growthThe company expects total revenue, product revenue, and BD-related revenue to all grow at double-digit rates even without new BD transactions.

Impact & implications

The implications for China's healthcare CXO and innovative drug value chain are positive: on one hand, leading CXO companies are improving growth visibility through commercial manufacturing, backlog, and high-barrier novel-modality platforms; on the other hand, AI is gradually moving from concept into business links such as protein synthesis, drug discovery, and enzyme discovery, driving both service demand and product revenue. For investors, the near-term focus is on FY26E guidance delivery, commercial project launches, and BD deal execution; medium- to long-term focus is on rising share of high-margin novel-modality businesses, the durability of AI-related demand, and capacity utilization after expansion.

Risks

• CXO companies' backlog conversion, commercial project launches, or capacity utilization could come in below management expectations.
• AI-assisted drug discovery demand may fluctuate in phases and may not continuously translate into high-quality revenue.
• Ramp-up of novel-modality businesses such as peptides, oligonucleotides, conjugation payloads, and biologics may be slower than expected, delaying margin improvement.
• Innovative drug BD transactions remain uncertain, and approvals, clinical data, and market competition may all affect valuation and growth delivery.
• This report is a conference note, mainly based on management statements, and lacks a full valuation model, target price, and itemized financial forecast validation.

What to watch

• Whether WuXi XDC launches its first BLA commercial project within the year, and whether XDP5 and XDP6 GMP readiness proceeds according to the 2027-2028 plan.
• The speed at which Asymchem converts its 2026 US$1.385bn backlog into revenue, and the degree of improvement in the share and gross margin of novel-modality businesses.
• Customer adoption of GenScript's TurboCHO Protein Expression Kits in markets outside China, and whether AIDD-related protein-synthesis demand can remain durable.
• The actual effectiveness of Bestzyme's use of AI to accelerate enzyme discovery and reduce costs.
• Whether Hansoh Pharma completes at least one new outbound-licensing BD transaction in 2026, and progress on Ameile and the EGFR/c-MET-related pipeline.
• Whether Legend's in-vivo CAR-T first-in-human data are disclosed at meetings such as EHA'26.